Multidose drug dispensing and discrepancies between medication records

Liv Johanne Wekre,1,2,3 Olav Spigset,4,5 Olav Sletvold,6,7 Janne Kutschera Sund,2 Anders Grimsmo1,3

ABSTRACT

Background The objective of this study was to investigate whether implementation of multidose drug dispensing (MDD) for elderly outpatients is associated with a change in the number of discrepancies in the medication record at the general practitioners (GPs) and at the community home-care services.

Methods A controlled follow-up study with paired design of patients’ medication records was performed during implementation of MDD. Medication records from the home care units and from the GPs were reviewed, and the discrepancies were noted. The discrepancies were rated into four classes based upon the potential harm, and a risk score system was applied, giving the potentially most harmful discrepancies the highest score.

Results Medication records from 59 patients with a mean age of 80 years were included. The number of discrepancies was reduced from 203 to 133 (p < 0.001), and the total risk score decreased from 308 to 181 (p < 0.001) after the implementation of MDD. For both drugs subject to MDD and drugs not suitable for MDD, the reductions in discrepancies were significant (39% and 31% reduction respectively).

Conclusions Calculated health risk due to discrepancies between the medication records from the home-care service and from the GPs decreased during the time of implementation of the MDD system. It seems likely that most of the positive effect was caused by the change in routines and enhanced focus on the medication process rather than by MDD per se.

INTRODUCTION

Incorrect use and incorrect handling of drugs is a major problem both in specialist care and in primary care.1 2 Even when limited to primary care, the number of adverse drug events has been seriously high in international studies.3–5 Both GPs and home-care services sense this problem and have expressed dissatisfaction with the collaboration regarding the medication of shared patients.5

In 1999, the Norwegian Board of Health initiated work on a plan of action aimed towards safer use of medicines. The focus was especially directed towards primary care services.6 A number of actions was suggested, one of which was the use of MDD in nursing homes and home-care services. MDD implies that patients receive their drugs machine-dispensed into one unit for each dose occasion, packed into disposable bags. The dose unit bags are labelled with patient data, drug contents data and time for intake.6–10

The number of MDD users is growing. In 2002, there were about 3000 MDD users in Norway; in 2006, the number had grown to 16,000 and in 2009 to approximately 35,000. Eighty per cent of the MDD users receive home-care service. There is an estimated potential of including a total of 200,000 patients from the primary care in Norway into the MDD system.11 12 MDD is expected to reduce medication errors, increase drug adherence and decrease waste of unused drugs.8 13–15 Still, more research is needed to document the effects of the system.12

Care of patients in their homes requires collaboration between GPs and home care providers who generally do not physically work together. Furthermore, GPs and home-care services maintain separate medication records for patients they have in common. In the MDD system, the pharmacy sets up one medication record for each MDD user, which is shared electronically with the company responsible for packing the multidose drugs. This record gives the pharmacist a complete overview of the patients’ drugs. It includes both drugs processed by the MDD system and drugs dispensed manually as before.

The aim of this study was to investigate whether the implementation of MDD for elderly outpatients was associated with a change in inconsistencies when comparing medication records from the GPs and the home-care services. We wanted to study both the number of discrepancies and the potential of the discrepancies to cause harm to the patients. To our knowledge, a controlled study such as this has not been conducted before.

METHODS

Ten home care units in the city of Trondheim, Norway, each recruited up to 15 patients for participation, selecting the first 15 patients on an alphabetical list. The nurses responsible for the implementation of MDD in the units performed the selection and obtained informed consent.

Medication records from the GPs and from the home-care services were collected half a year before and 1 year after the implementation of MDD. After the implementation, medication records from the pharmacies responsible for delivering the MD packages were provided as well. The study ran from May 2006 to January 2008.

The primary outcome was discrepancies between the patients’ medication records at the GPs and at the home-care services, and the number of drugs in the GPs’ medication records. The discrepancies were rated for their potential to cause patient harm by a team consisting of two pharmacists, a GP, a clinical pharmacologist and a geriatrician. Each member of the team made an individual assessment...
Table 1 Classification of discrepancies according to potential harm

<table>
<thead>
<tr>
<th>Class</th>
<th>Description</th>
<th>No of discrepancies before MDD</th>
<th>No of discrepancies after MDD</th>
<th>Absolute reduction in the percentage of discrepancies (95% CI)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class 0</td>
<td>It could not be decided with certainty whether the discrepancy was a true discrepancy or not. An example is lack of information on vitamin B12 injections in the home-care service record.</td>
<td>6 (1%)</td>
<td>0 (0%)</td>
<td>100% (95.1% to 100%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Class 1</td>
<td>Discrepancies unlikely to cause patient discomfort or clinical deterioration. An example would be prescription discrepancies in timing of the dose where this was considered unimportant, or discrepancies involving drugs considered not potent (eg, some vitamins).</td>
<td>25 (6%)</td>
<td>15 (3%)</td>
<td>40% (26.9% to 53.1%)</td>
<td>0.001</td>
</tr>
<tr>
<td>Class 2</td>
<td>Discrepancies with the potential to cause moderate discomfort or clinical deterioration. An example would be when warfarin was missing in one of the two records.</td>
<td>156 (39%)</td>
<td>101 (24%)</td>
<td>35% (28.6% to 41.4%)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Class 3</td>
<td>Discrepancies with the potential to result in severe discomfort or clinical deterioration. An example would be when warfarin was missing in one of the two records.</td>
<td>137 (34%)</td>
<td>22 (5%)</td>
<td>85% (77.3% to 92.1%)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

RESULTS

In total, 136 patients were included after the first collection of medication records. However, only 59 patients (43%) remained in the final material. The 77 drop-outs were as follows: 43 patients were not considered suitable for using MDD or did not receive home care when MDD was implemented, 20 patients had had MDD for a period of time but quit before the last collection of medication records, and 14 patients did receive MDD at the time of evaluation, but not all medication records were available (eight records missing from the GPs, three records missing from the home-care services and three records missing from the pharmacies). The patients had a mean age of 80 years at study start, ranging from 52 to 92 years. Forty-six (78%) of the patients were female. For comparison, the dropout patients had a mean age of 78 years, ranging from 54 to 98 years, and 56% were female.

The total number of drugs listed in the 59 medical records from the GPs was 386 before the implementation of MDD and 424 after the implementation (p=0.016). Before the implementation, there were 47 medication records (80%) with discrepancies, as compared with 45 records (76%) with discrepancies after the implementation (p=0.774).

In total, there was a 34% reduction in the number of discrepancies after implementation of MDD (p<0.001). The risk classification of the discrepancies is presented in table 2. For drugs subject to MDD, the reduction in the number of discrepancies was 59%, whereas for drugs not suitable for MDD (eg, injections, mixtures, eye-drops) and drugs to be used as required, the reduction was 51%. Table 3 shows the number of discrepancies for these three groups.

The various types of discrepancies are presented in table 4. The most frequent type of discrepancy both before and after implementation of MDD was that a prescription in the GP’s record was lacking in the home-care services record. The second most frequent discrepancy was that a prescription in the GP’s record was lacking in the home-care services record.

For all the 59 pairs of medication records, there was a total risk score of 308 before the implementation and 181 after the implementation of MDD (p<0.001). There was also a significant risk reduction after implementation of MDD (p=0.001).
reduction in the number of high-risk medication records during the implementation of MDD (p<0.02) (table 5).

When the medication records at the GPs and at the home-care services were compared with the records from the pharmacies after implementation of MDD, we found 151 discrepancies. There were discrepancies between the pharmacy record and the GP record in 49 drug prescriptions and between the pharmacy record and the home-care services record in 133 drug prescriptions. In 31 drug prescriptions the pharmacy record neither agreed with the GP record nor the home-care service record.

**DISCUSSION**

Results from this study show a better agreement between the information in the medication records from the GPs and at the home-care services after the implementation of MDD compared with before the implementation. This improvement caused a drop in estimated health risks due to discrepancies in spite of a registered increase in the number of drugs in the medication records.

A significant reduction in the number of discrepancies was seen not only for the drugs subject to MDD, but also for the drugs not suitable for MDD (table 5). This finding supports the assumption that changes in routines constitute a central factor in the improvement and that the improvement is not necessarily due to the MDD alone. The improvement could be attributed to the implementation process itself, and to the work done by the different participants. The amount of allocated resources, the mandate from the city council to the implementation team and other routines adopted could also be of importance.

In previous Norwegian studies, it has been shown that up to 90% of the patients had one or more discrepancies in their medication records at the home-care services compared with the medication record at the GP, whereas we found 80% before the implementation of MDD. A study from 2004 showed that there were discrepancies in records belonging to patients receiving MDD as well. Regarding the GPs’ and home-care services’ records, discrepancies were disclosed in 52% of the patients in that study, whereas we found that 76% of the multidose patients had at least one discrepancy. A small study from 2001 indicated that MDD causes no better agreement in medication records than manual dispensing of drugs. This may again indicate that the established routines in the home-care services, at the GPs and at the pharmacies, together with the information work accomplished during the implementation of MDD, are important factors in order to achieve improved drug safety in the MDD system.

The home-care services in Trondheim have used electronic health records (EHRs) since 1996, and its medication module regularly since 1998. This should be accounted for when comparing the results with the findings from other studies since EHRs are not yet common everywhere. All medication records from the community home-care services that we used in the present study were printed out from the EHR.

Ninety-eight per cent of GPs in Norway have EHRs, but even though all of them use the EHR when printing out single prescriptions, the updating of the patient medication record has not been carried out systematically. Before the implementation of MDD, 10 of the included medication records from the GPs were not printed out from the EHR medication module, as compared with only one after the implementation. The better routines among GPs in updating the medication records probably contributed to the reduction in discrepancies that we found.

We found a reduced number of discrepancies and a decrease in estimated health risks due to discrepancies in the medication records after the implementation of MDD. Studies show, however, that a reduction in prescribing errors will not necessarily be followed by a decrease in adverse drug events. Handling of the medication after removing it from the packaging may still contribute to a high error frequency.
the other hand, the MDD system may reduce the number of prescribers, which is an independent risk factor.²⁸

### Limitations of the study

The dropout rate was large, 57%. Since the study population was old, and not all patients are suited for MDD, this was expected. Twenty patients (15%) in the dropout group had received MDD in a period of time before the follow-up. We cannot exclude with certainty that some of them may have died from reasons connected to the implementation of MDD, but we do not have any information that this did happen.

Use of multiple statistical testing can inflate the type I error rate, so some of the statistically significant findings could be spurious, and the small sample size means that some possibly important differences could have been missed.

We considered the selection of patients from an alphabetical list to be convenient. As the selection was done by the last names of the patients, the risk of drawing family members could be increased. However, the patients were recruited from 10 different home care units, and we do not consider that this procedure has introduced any relevant bias.

The implementation process in Trondheim precluded the possibility of including a control of patients not subject to MDD from the same municipality. Including an external control group would involve a different organisation prone to be infeasible by other factors in the study period. Instead, we made an internal control by comparing drugs subject to MDD and drugs not suitable for MDD. Changes in the latter group should not be caused by the introduction of the MDD system per se, but if such changes occurred, they should be due to other elements common to both groups.

Access to clinical data could have made the classification of the discrepancies more reliable.¹⁷¹⁸ However, the classification used in this study has also been used by others based on drug information data alone and is validated for use in settings like the present one. This study has also been used by others based on drug information 4 of 4

### Table 5

<table>
<thead>
<tr>
<th>High-risk medication record before implementation</th>
<th>High-risk medication record after implementation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes</td>
</tr>
<tr>
<td>Yes</td>
<td>8</td>
</tr>
<tr>
<td>No</td>
<td>6</td>
</tr>
<tr>
<td>Total</td>
<td>14</td>
</tr>
</tbody>
</table>

Acknowledgements We thank the GPs and the personnel at the home-care services and at the pharmacies for their time spent on the study. Thanks to Helge Gåråsen and members of the council implementation group for the support given. We also acknowledge E Baukål Richeim, for her work with the study during her Master’s thesis, and Pål Rønndalstad, for help with the statistics.

Funding Liaison Committee between the Central Norwegian Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU).

Competing interests None.

Patient consent Obtained.

Ethics approval Ethics approval was provided by the Regional Committee for Medical Research Ethics (REK) and the Norwegian Data Inspectorate (NSD).

Provenance and peer review Not commissioned, externally peer reviewed.

### REFERENCES